Invention Grant
- Patent Title: RNAi-mediated inhibition of connexin 43 for treatment of IOP-related conditions
-
Application No.: US15277058Application Date: 2016-09-27
-
Publication No.: US09752147B2Publication Date: 2017-09-05
- Inventor: Jon E. Chatterton , Abbot F. Clark , Martin B. Wax
- Applicant: Arrowhead Pharmaceuticals, Inc.
- Applicant Address: US CA Pasadena
- Assignee: Arrowhead Pharmaceuticals, Inc.
- Current Assignee: Arrowhead Pharmaceuticals, Inc.
- Current Assignee Address: US CA Pasadena
- Agent Robert Michael Teigen
- Main IPC: A61K48/00
- IPC: A61K48/00 ; C12N15/11 ; C12N15/113 ; A61K31/713
Abstract:
RNA interference is provided for inhibition of connexin 43 (Cx43) in intraocular pressure-related conditions, including ocular hypertension and glaucoma such as normal tension glaucoma and open angle glaucoma.
Public/Granted literature
- US20170009235A1 RNAi-MEDIATED INHIBITION OF CONNEXIN 43 FOR TREATMENT OF IOP-RELATED CONDITIONS Public/Granted day:2017-01-12
Information query
